Preparation method of compound amino acid composition without antioxidant
By controlling the oxygen content and dissolution of raw materials, designing a preparation method for compound amino acid compositions without antioxidants, solving the instability of cystine in alkaline solutions, improving the safety and stability of the product, and optimizing the safety and stability of the product. Products available on the market.
Patent Information
- Application Number
- CN202211709260.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-29
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-12-29
AI Technical Summary
Existing compound amino acid preparations often contain antioxidants, such as sulfites, which are prone to allergic reactions and toxic effects, especially in susceptible people, and it is difficult to avoid oxidation under cystine-containing conditions.
By controlling the oxygen content and raw material dissolution method in the production process, a preparation method for a compound amino acid composition without antioxidants is designed, and other amino acids are dissolved using sodium hydroxide to form a second medicine solution, and cystine is dissolved with hydrochloric acid. A third medicine solution is formed and added slowly to improve its stability and avoid the influence of instability in the alkaline solution.
It effectively avoids the toxic effects caused by antioxidants, improves the safety of clinical drugs, and maintains the stability of the product without antioxidants, which is better than the quality of commercially available compound amino acid compositions.
Smart Images

Figure BDA0004026859010000071 
Figure BDA0004026859010000081 
Figure BDA0004026859010000091
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of compound amino acid preparations, and in particular to a method for preparing a compound amino acid composition free of antioxidants. Background Art
[0002] Since amino acids (especially cystine) are unstable, they are easily oxidized when in contact with air during the production process, causing the solution to turn yellow. In order to ensure the stability of product quality, most of the compound amino acid preparations containing cystine currently on the market contain antioxidants (mainly sulfites) to solve the problem of unstable amino acids being easily oxidized. However, since sulfites are prone to cause allergic reactions in susceptible populations (such as asthmatics), and even induce toxic effects, increasing the risk of clinical application, compound amino acid preparations that do not contain sulfites or have a lower sulfite content are preferred for patients with long-term parenteral nutrition, dysfunction of important organs, critical illness, children, the elderly, and a history of high-risk allergies. European and American countries have formally required pharmaceutical manufacturers to indicate the content of added antioxidants and their adverse reactions in the drug instructions. The "Announcement of the General Administration on the Revision of the Instructions for Compound Amino Acid Injection (18AA) and Similar Preparations" issued by the State Food and Drug Administration (CFDA) in September 2016 also made the same requirement. Therefore, how to reduce the amount of antioxidants in compound amino acid compositions or even not use antioxidants at all is the current research focus.
[0003] In the prior art, in order to reduce the amount of antioxidants in the recurrent amino acid composition, most of them are to avoid amino acid oxidation by controlling the oxygen content in the production process. For example, the patent with publication number CN109381423A discloses a preparation method of a pharmaceutical composition containing 19 kinds of amino acids, the pharmaceutical composition comprises 19 kinds of amino acids, a pH regulator and water, and controls the content of dissolved oxygen in the injection and the headspace oxygen in the injection storage container, so that it can be stably present under the condition of not containing pyrosulfite or sulfite antioxidants, and then thoroughly solves the harm of pyrosulfite or sulfite antioxidants to human body. However, the pharmaceutical composition provided by the patent does not contain cystine in substance, but uses cysteine, which is also a broad antioxidant in itself, and has a certain antioxidant effect. If very unstable cystine is added to the amino acid injection, and cysteine that can be used as an antioxidant is not added at the same time, it is difficult to avoid cystine oxidation only by controlling the oxygen content.
[0004] In view of this, it is necessary to design an improved method for preparing a compound amino acid composition without antioxidants to solve the above problems. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, the object of the present invention is to provide a method for preparing a compound amino acid composition containing cystine but not cysteine and other antioxidants, thereby improving the safety of clinical medication while removing the antioxidants and ensuring product quality.
[0006] To achieve the above object, the present invention provides a method for preparing a compound amino acid composition without an antioxidant, comprising the following steps:
[0007] S1. Flushing and passivation of the liquid distribution system and pipelines;
[0008] S2, adding a predetermined amount of water for injection into a batching device, filling nitrogen into the batching device until the amount of dissolved oxygen in the liquid reaches a predetermined range, and then adding sodium hydroxide to obtain a first liquid medicine;
[0009] S3, after heating the first liquid to a predetermined temperature, adding one or more amino acids selected from tyrosine, lysine, methionine, threonine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, phenylalanine, histidine, taurine, and tryptophan, and three amino acids selected from isoleucine, leucine, and valine, and stirring and dissolving them one by one to obtain a second liquid;
[0010] S4, dissolving cystine with a hydrochloric acid solution to obtain a third liquid;
[0011] S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount, and stirring at a temperature of 100°C to obtain a fourth liquid medicine;
[0012] S6. After adding a pH adjuster to adjust the pH of the fourth liquid, the fourth liquid is packaged and sterilized to obtain a compound amino acid composition without an antioxidant.
[0013] As a further improvement of the present invention, for each preparation of 10000 mL of the compound amino acid composition, the amount of each raw material is: tyrosine 0-30g, lysine 0-150g, methionine 0-60g, threonine 0-60g, alanine 0-180g, arginine 0-130g, aspartic acid 0-40g, glutamic acid 0-60g, proline 0-80g, serine 0-50g, glycine 0-85g, phenylalanine 0-85g, histidine 0-75g, taurine 0-20g, tryptophan 0-25g, isoleucine 10-100g, leucine 20-150g, valine 25-80g, cystine 0.5-5g, and sodium hydroxide 11-13g added in step S2; the sodium hydroxide added in step S2 is added to the batching device in solid form, or is pre-prepared into a sodium hydroxide solution and then added to the batching device, and the concentration of the sodium hydroxide solution is 1%-20%, preferably 5%-15%, and more preferably 10%.
[0014] As a further improvement of the present invention, in step S4, the concentration of the hydrochloric acid solution is 0.8-1.2 mol / L, preferably 1 mol / L; and the amount of the hydrochloric acid solution added is 20-100 mL for every 10000 mL of the compound amino acid composition.
[0015] As a further improvement of the present invention, in step S1, the flushing passivation includes the following steps:
[0016] First, the liquid preparation system and pipeline are circulated and flushed with sodium carbonate solution, and after the sodium carbonate solution is completely drained, the liquid preparation system and pipeline are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm;
[0017] Then, the disodium edetate solution is used to circulate and flush the liquid preparation system and pipelines. After the disodium edetate solution is completely discharged, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm.
[0018] As a further improvement of the present invention, in step S2, the amount of the water for injection is 40% to 70% of the total amount, preferably 50%; the predetermined range of the amount of dissolved oxygen in the liquid is ≦500PPBO2.
[0019] As a further improvement of the present invention, in step S3, the first medicinal solution is heated to 40-80°C, preferably 45-55°C; each amino acid added in step S3 is added in the form of its free base or salt, and the salt form includes hydrochloride or acetate.
[0020] As a further improvement of the present invention, in step S5, the insulation temperature is 50±5°C, and the insulation stirring time is 5 to 30 minutes, preferably 10 to 25 minutes.
[0021] As a further improvement of the present invention, in step S6, the pH adjuster is a sodium hydroxide solution, which is used to adjust the pH value of the fourth liquid medicine to 5.0-7.0; the concentration of the sodium hydroxide solution is 8%-12%, preferably 10%.
[0022] As a further improvement of the present invention, in step S6, the residual oxygen content is controlled at 0-3.0%, preferably 0-1.5%, and more preferably 0-1.0% during filling; the sterilization adopts the overkill method, and the sterilization conditions are sterilization at 121°C for 12-30 minutes.
[0023] As a further improvement of the present invention, it also includes the addition of in vitro nutritional supplements; the in vitro nutritional supplements are preferably one or more of sorbitol, xylitol, glucose, calcium gluconate, potassium chloride, sodium chloride, calcium chloride, chromium chloride, cupric sulfate, ferrous sulfate, magnesium sulfate, zinc chloride, cupric chloride, manganese chloride, and sodium selenite.
[0024] The beneficial effects of the present invention are:
[0025] 1. The preparation method of the antioxidant-free compound amino acid composition provided by the present invention comprises the following steps: by controlling the adding method of cystine, firstly dissolving the amino acids other than cystine with sodium hydroxide at a relatively high temperature to prepare a second liquid; dissolving cystine alone with a hydrochloric acid solution to form a third liquid, so that cystine exhibits relatively high stability in the hydrochloric acid solution; and then slowly adding the third liquid into the second liquid, thereby effectively avoiding the influence of the instability of cystine in an alkaline solution on the product quality.
[0026] 2. The present invention simultaneously regulates the oxygen content of the production process, the dissolution mode of the raw materials and the order of addition, and can still not add antioxidants under the condition of using cystine, avoiding the toxic effects caused by the addition of antioxidants, solving the clinical risks of products containing antioxidants from the root, and improving the safety of clinical medication. In addition, the compound amino acid composition provided by the present invention can still ensure the stability of the product during storage, transportation, and use without containing antioxidants, and will not cause the product quality to decline due to the instability of amino acids. Instead, it can avoid the problem of cystine being consumed in large quantities by antioxidants due to the presence of antioxidants, making the product quality better than the current commercially available compound amino acid composition containing antioxidants. DETAILED DESCRIPTION
[0027] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is described in detail below in conjunction with specific embodiments.
[0028] In addition, it should be noted that the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.
[0029] The present invention provides a method for preparing a composite amino acid composition without an antioxidant, comprising the following steps:
[0030] S1. Flushing and passivation of the liquid distribution system and pipelines;
[0031] S2, adding a predetermined amount of water for injection into a batching device, filling nitrogen into the batching device until the amount of dissolved oxygen in the liquid reaches a predetermined range, and then adding sodium hydroxide to obtain a first liquid medicine;
[0032] S3, after heating the first liquid to a predetermined temperature, adding one or more amino acids selected from tyrosine, lysine, methionine, threonine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, phenylalanine, histidine, taurine, and tryptophan, and three amino acids selected from isoleucine, leucine, and valine, and stirring and dissolving them one by one to obtain a second liquid;
[0033] S4, dissolving cystine with a hydrochloric acid solution to obtain a third liquid;
[0034] S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount, and stirring at a temperature of 100°C to obtain a fourth liquid medicine;
[0035] S6. After adding a pH adjuster to adjust the pH of the fourth liquid, the fourth liquid is packaged and sterilized to obtain a compound amino acid composition without an antioxidant.
[0036] Through the above method, the stability of cystine can be effectively improved, and the influence of the instability of cystine in alkaline solution on the product quality can be avoided, so that the stability of the product during storage, transportation and use can be guaranteed while not containing antioxidants, and the product quality of the compound amino acid composition can be improved.
[0037] Specifically, for each preparation of 10000 mL of the compound amino acid composition, the dosage of each amino acid is: tyrosine 0-30 g, lysine 0-150 g, methionine 0-60 g, threonine 0-60 g, alanine 0-180 g, arginine 0-130 g, aspartic acid 0-40 g, glutamic acid 0-60 g, proline 0-80 g, serine 0-50 g, glycine 0-85 g, phenylalanine 0-85 g, histidine 0-75 g, taurine 0-20 g, tryptophan 0-25 g, isoleucine 10-100 g, leucine 20-150 g, valine 25-80 g, and cystine 0.5-5 g.
[0038] For each preparation of 10000 mL of the compound amino acid composition, the mass of the sodium hydroxide added in step S2 is 11-13 g, and the sodium hydroxide is added to the batching device in solid form, or is pre-prepared into a sodium hydroxide solution and then added to the batching device. The concentration (mass concentration) of the sodium hydroxide solution is 1% to 20%, preferably 5% to 15%, and more preferably 10%.
[0039] In step S1, the flushing passivation comprises the following steps:
[0040] First, the liquid preparation system and pipelines are circulated and flushed with sodium carbonate solution, and after the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm;
[0041] Then, the disodium edetate solution is used to circulate and flush the liquid preparation system and pipelines. After the disodium edetate solution is completely discharged, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm.
[0042] In step S2, the amount of water for injection is 40% to 70% of the total amount, preferably 50%; the predetermined range of the amount of dissolved oxygen is ≦500 PPBO2; and the total amount is the total volume of the compound amino acid composition to be prepared.
[0043] In step S3, the first drug solution is heated to 40-80°C, preferably 45-55°C; each amino acid added in step S3 is added in the form of its free base or salt, and the salt form includes hydrochloride or acetate.
[0044] In step S4, the concentration of the hydrochloric acid solution is 0.8-1.2 mol / L, preferably 1 mol / L; for every 10000 mL of the compound amino acid composition, the amount of the hydrochloric acid solution added is 20-100 mL.
[0045] In step S5, the insulation temperature is 50±5°C, and the insulation stirring time is 5 to 30 minutes, preferably 10 to 25 minutes.
[0046] In step S6, the pH adjuster is a sodium hydroxide solution, which is used to adjust the pH value of the fourth liquid medicine to 5.1-6.5; the concentration (mass concentration) of the sodium hydroxide solution is 8%-12%, preferably 10%; during the filling, the residual oxygen content is controlled at 0-3.0%, preferably 0-1.5%, and more preferably 0-1.0%; the sterilization adopts the overkill method, and the sterilization conditions are sterilization at 121°C for 12-30 minutes.
[0047] In some embodiments of the present invention, an in vitro nutritional supplement may be added during the preparation of the compound amino acid composition. The in vitro nutritional supplement may be added together with each amino acid in step S3, or may be added in an additional step; the in vitro nutritional supplement is preferably one or more of sorbitol, xylitol, glucose, calcium gluconate, potassium chloride, sodium chloride, calcium chloride, chromium chloride, copper sulfate, ferrous sulfate, magnesium sulfate, zinc chloride, copper chloride, manganese chloride, and sodium selenite.
[0048] The preparation method of the antioxidant-free compound amino acid composition provided by the present invention is described below with reference to specific examples.
[0049] Embodiments 1 to 5
[0050] Examples 1 to 5 provide a composite amino acid composition without an antioxidant. Taking the preparation of 10000 mL of the composite amino acid composition as an example, the corresponding prescription amounts of each raw material in each example are shown in Table 1.
[0051] Table 1 Prescription amount of each raw material in the compound amino acid composition without antioxidant provided in Examples 1 to 5
[0052]
[0053]
[0054] Examples 1 to 5 also provide methods for preparing the above-mentioned antioxidant-free composite amino acid composition. The difference between the embodiments mainly lies in the different compositions. The preparation methods all include the following steps:
[0055] S1. Flushing and passivation of the liquid distribution system and pipelines:
[0056] First, the liquid preparation system and pipelines are circulated and flushed with 3% sodium carbonate solution for 20 minutes. After the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the rinse water is the same as that of the injection water and the conductivity is less than 1μs / cm.
[0057] Then, the disodium edetate solution of 1‰ (g / mL) was used to circulate and flush the disodium edetate system and pipelines for 20 minutes. After the disodium edetate solution was completely drained, it was flushed with water for injection until the pH value of the rinse water was the same as that of the water for injection and the conductivity was less than 1μs / cm, thus completing the flushing passivation of the disodium edetate system and pipelines.
[0058] S2. Add 5000mL (50% of the total amount) of water for injection into the batching tank, start stirring and open the nitrogen valve, fill the batching tank with nitrogen while stirring until the dissolved oxygen content of the liquid is ≦500PPBO2, and then add the prescribed amount of sodium hydroxide (dissolve the prescribed amount of sodium hydroxide in water for injection and dilute it to a concentration of 10% before adding) to obtain the first liquid medicine;
[0059] S3, turning on the steam to heat the first liquid medicine to 50±5°C and maintaining it, then adding the prescribed amount of tyrosine, isoleucine, leucine, lysine, methionine, threonine, valine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, sorbitol, phenylalanine, histidine, taurine, and tryptophan in order according to the prescription sequence, and stirring and dissolving them one by one to obtain a second liquid medicine;
[0060] S4, dissolving the prescribed amount of cystine with a 1 mol / L hydrochloric acid solution to obtain a third liquid;
[0061] S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount (10000mL), and stirring at 50±5°C for 15min to obtain a fourth liquid medicine;
[0062] S6, add 10% sodium hydroxide solution as a pH regulator, adjust the pH value of the third liquid to a predetermined value (pH adjusted to 6.0 in Example 1, pH adjusted to 5.6 in Example 2, pH adjusted to 5.6 in Example 3, pH adjusted to 5.6 in Example 4, pH adjusted to 5.5 in Example 5), continue stirring for 30 minutes and then stop stirring, pump the liquid into the liquid storage tank for standby use. After the liquid is tested to be qualified, fill it with nitrogen and fill it in an infusion bottle, and control the residual oxygen content to be below 1.0% during the filling process; then use the overkill method for sterilization, the sterilization conditions are 121°C, 12 minutes, and after sterilization, a compound amino acid composition without antioxidants is obtained.
[0063] In order to test the stability of the antioxidant-free compound amino acid composition prepared in Examples 1 to 4, a long-term stability experiment was conducted on the compound amino acid composition prepared in each Example, with pH, transmittance (%), insoluble particles, related substances, and amino acid content as key evaluation indicators, and sampling and testing were performed at 0, 3, 6, 9, 12, and 24 months, respectively, to investigate the stability of the prepared products, and Example 1 was compared with commercially available product 1 (compound amino acid composition (18AA) produced by Anhui Shuanghe Pharmaceutical Co., Ltd., the product contains the antioxidant sodium bisulfite), and Examples 2 to 4 were compared with commercially available product 2 (compound amino acid injection (18AA-II) produced by Guangdong Otsuka Pharmaceutical Co., Ltd., the product contains the antioxidant sodium pyrosulfite), and the results are shown in Tables 2 and 3, respectively.
[0064] Table 2 Performance comparison of the antioxidant-free compound amino acid composition prepared in Example 1 and commercially available product 1
[0065]
[0066]
[0067]
[0068]
[0069] Table 3 Performance comparison of the antioxidant-free compound amino acid composition prepared in Examples 2 to 4 and commercially available product 2
[0070]
[0071]
[0072]
[0073]
[0074]
[0075] It can be seen from Table 2 and Table 3 that although the compound amino acid compositions prepared in Examples 1 to 4 do not contain any antioxidants, after being stored under long-term conditions for 24 months, the key evaluation indicators have no significant difference from those when the initial preparation is completed, indicating that the preparations prepared by the present invention can still maintain good product stability without adding antioxidants.
[0076] At the same time, since the antioxidant sodium bisulfite present in commercial product 1 consumes cystine, the actual content of cystine is greatly reduced, which seriously affects the patient's extraction of cystine; the antioxidant sodium pyrosulfite present in commercial product 2 also consumes cystine, resulting in a decrease in the actual content of cystine. The cystine in commercial product 2 is close to the quality control line after being placed for 24 hours (the Chinese Pharmacopoeia 2020 version stipulates that the cystine content range is 80.0% to 120.0%), which will also affect the patient's extraction of cystine. The antioxidant-free compound amino acid composition prepared in Examples 1 to 4 can effectively avoid the problem of cystine being consumed in large quantities by antioxidants due to the presence of antioxidants, and significantly increase the content of cystine in the compound amino acid composition, which has quality attributes that are significantly better than commercially available products.
[0077] Comparative Examples 1 to 3
[0078] Comparative Examples 1 to 3 respectively provide a compound amino acid composition without an antioxidant. Among them, Comparative Example 1 is based on Example 1, and only the method of adding cystine in step S4 is changed. Instead of dissolving cystine alone with a hydrochloric acid solution, cystine is directly added to a second liquid with sodium hydroxide as a cosolvent, and the remaining steps and the prescription amount of raw materials are consistent with those of Example 1; Comparative Example 2 is based on Example 2, and cystine is directly added to a second liquid with sodium hydroxide as a cosolvent in the same manner as Comparative Example 1, and the remaining steps and the prescription amount of raw materials are consistent with those of Example 2; Comparative Example 3 is based on Example 5, and cystine is directly added to a second liquid with sodium hydroxide as a cosolvent in the same manner as Comparative Example 1, and the remaining steps and the prescription amount of raw materials are consistent with those of Example 5, which are not repeated here.
[0079] The transmittance of the compound amino acid composition obtained in Comparative Examples 1 to 2 was detected and compared with Examples 1 to 2 and commercially available products 1 to 2; at the same time, the transmittance of Example 5 and Comparative Example 3 was detected, and the two were compared with Example 5. The results are shown in Table 4, Table 5, and Table 6, respectively.
[0080] Table 4 Performance comparison of Example 1, Comparative Example 1 and Commercially available product 1
[0081]
[0082]
[0083] Table 5 Performance comparison of Example 2, Comparative Example 2, and Commercially available product 2
[0084]
[0085] Table 6 Performance comparison of Example 5 and Comparative Example 3
[0086]
[0087] It can be seen from Table 4, Table 5 and Table 6 that Comparative Example 1, Comparative Example 2 and Comparative Example 3 use a conventional method to directly add cystine to the second liquid with sodium hydroxide as a co-solvent. Since no antioxidant is added, the transmittance of the prepared compound amino acid composition cannot meet the corresponding limit requirements, and the product quality does not meet the standards; and since antioxidants are added to Commercially Available Products 1 and Commercially Available Products 2, although the corresponding limit requirements can be met, the addition of antioxidants also increases the risk of clinical application and will affect the actual content of cystine.
[0088] Compared with Comparative Examples 1-2 and commercially available products 1-2, Examples 1-2 adjust the addition method of cystine, dissolve cystine alone in hydrochloric acid solution to form a third liquid, and then add it to the second liquid formed by other amino acids with sodium hydroxide as a cosolvent, so that it can still meet the corresponding limit requirements after being placed for 24 months without adding any antioxidants. Its light transmittance at each time stage is even higher than that of commercially available products 1-2 with added antioxidants, showing higher stability. At the same time, it avoids the clinical risks caused by the addition of antioxidants and the problem of cystine being consumed, and its product quality is significantly better than commercially available products 1-2 containing antioxidants. Similarly, compared with Comparative Example 3, Example 5 significantly improves the stability of the product prepared by treating cystine alone with hydrochloric acid solution and then adding it to the second liquid mixed with other amino acids.
[0089] Example 6
[0090] This embodiment provides a method for preparing a compound amino acid composition without an antioxidant. Compared with Example 1, the difference is that the sterilization conditions in step S6 are changed. The sterilization conditions in this embodiment are 121° C. and 15 min. The remaining steps are consistent with Example 1 and will not be repeated here.
[0091] Compared with Example 1, this example significantly improves the sterility assurance level of the product by extending the sterilization time and using an overkilling method. However, most of the compound amino acid products currently on the market use auxiliary sterilization methods, which poses a safety hazard in clinical use.
[0092] In summary, the present invention provides a method for preparing a compound amino acid composition that does not contain an antioxidant. The preparation method includes flushing and passivating the liquid preparation system and pipelines; after nitrogen is filled into the batching device for adding water for injection to adjust the dissolved oxygen content of the liquid, sodium hydroxide is added, and then the liquid is heated and other amino acids other than cystine are added one by one to obtain a second liquid; after cystine is dissolved in a hydrochloric acid solution to form a third liquid, the third liquid is added to the second liquid, and after constant volume, pH adjustment, filling, sterilization and other processes, a compound amino acid composition that does not contain an antioxidant is obtained. Through the above-mentioned method, the present invention can make cystine show higher stability, and can still ensure the stability of the product during storage, transportation and use without adding antioxidants, which not only improves the safety of clinical medication, but also improves product quality.
[0093] The above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing a compound amino acid composition without an antioxidant, characterized in that: The steps include: S1. Flushing and passivation of the liquid distribution system and pipelines; S2, adding a predetermined amount of water for injection into a batching device, filling nitrogen into the batching device until the amount of dissolved oxygen in the liquid reaches a predetermined range, and then adding sodium hydroxide to obtain a first liquid medicine; S3, heating the first liquid to 45-55° C., adding one or more amino acids selected from tyrosine, lysine, methionine, threonine, alanine, arginine, aspartic acid, glutamic acid, proline, serine, glycine, phenylalanine, histidine, taurine, and tryptophan, and three amino acids selected from isoleucine, leucine, and valine, and stirring and dissolving them one by one to obtain a second liquid; S4, dissolving cystine with a hydrochloric acid solution to obtain a third liquid; the concentration of the hydrochloric acid solution is 0.8-1.2 mol / L; S5, adding the third liquid medicine to the second liquid medicine, and then using water for injection to make up to the full amount, and stirring at a temperature of 100°C to obtain a fourth liquid medicine; S6, adding a pH adjuster to adjust the pH value of the fourth liquid to 5.0-7.0, and filling and sterilizing to obtain a compound amino acid composition without an antioxidant; For each preparation of 10000 mL of the compound amino acid composition, 11-13 g of sodium hydroxide is added in step S2, and 20-100 mL of the hydrochloric acid solution is added in step S4.
2. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: For each preparation of 10000 mL of the compound amino acid composition, the amount of each raw material is: 0-30 g tyrosine, 0-150 g lysine, 0-60 g methionine, 0-60 g threonine, 0-180 g alanine, 0-130 g arginine, 0-40 g aspartic acid, 0-60 g glutamic acid, 0-80 g proline, 0-50 g serine, 0-85 g glycine, 0-85 g phenylalanine, 0-75 g histidine, 0-20 g taurine, 0-25 g tryptophan, 10-100 g isoleucine, 20-150 g leucine, 25-80 g valine, and 0.5-5 g cystine; the sodium hydroxide added in step S2 is put into the batching device in solid form, or is pre-prepared into a sodium hydroxide solution and then put into the batching device, and the concentration of the sodium hydroxide solution is 1%-20%.
3. The method for preparing the antioxidant-free compound amino acid composition according to claim 2, characterized in that: The concentration of the sodium hydroxide solution is 5% to 15%.
4. The method for preparing the antioxidant-free compound amino acid composition according to claim 2, characterized in that: The concentration of the sodium hydroxide solution is 10%.
5. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: In step S4, the concentration of the hydrochloric acid solution is 1 mol / L.
6. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: In step S1, the flushing passivation comprises the following steps: First, the liquid preparation system and pipelines are circulated and flushed with sodium carbonate solution. After the sodium carbonate solution is completely drained, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm. Then, the disodium edetate solution is used to circulate and flush the liquid preparation system and pipelines. After the disodium edetate solution is completely discharged, the liquid preparation system and pipelines are flushed with injection water until the pH value of the flushing water is 5.0-7.0 and the conductivity is less than 1 μs / cm.
7. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: In step S2, the amount of water for injection is 40% to 70% of the total amount; the predetermined range of the amount of dissolved oxygen in the liquid is ≦500 PPBO2.
8. The method for preparing the antioxidant-free compound amino acid composition according to claim 7, characterized in that: In step S2, the amount of water for injection is 50% of the total amount.
9. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: Each amino acid added in step S3 is added in the form of its free base or salt, and the salt form includes hydrochloride or acetate.
10. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: In step S5, the insulation temperature is 50±5° C., and the insulation stirring time is 5 to 30 minutes.
11. The method for preparing the antioxidant-free compound amino acid composition according to claim 10, characterized in that: The time of heat preservation and stirring is 10 to 25 minutes.
12. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: In step S6, the pH adjuster is a sodium hydroxide solution; the concentration of the sodium hydroxide solution is 8% to 12%.
13. The method for preparing the antioxidant-free compound amino acid composition according to claim 12, characterized in that: The concentration of the sodium hydroxide solution is 10%.
14. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: In step S6, the residual oxygen content is controlled at 0-3.0% during the filling; the sterilization adopts the overkill method, and the sterilization condition is sterilization at 121° C. for 12-30 minutes.
15. The method for preparing the antioxidant-free compound amino acid composition according to claim 14, characterized in that: During the filling, the residual oxygen content is controlled at 0-1.5%.
16. The method for preparing the antioxidant-free composite amino acid composition according to claim 14, characterized in that: During the filling, the residual oxygen content is controlled at 0-1.0%.
17. The method for preparing the antioxidant-free compound amino acid composition according to claim 1, characterized in that: It also includes the addition of in vitro nutritional supplements.
18. The method for preparing the antioxidant-free composite amino acid composition according to claim 17, characterized in that: The in vitro nutritional supplement is one or more of sorbitol, xylitol, glucose, calcium gluconate, potassium chloride, sodium chloride, calcium chloride, chromium chloride, cupric sulfate, ferrous sulfate, magnesium sulfate, zinc chloride, cupric chloride, manganese chloride, and sodium selenite.
Citation Information
Patent Citations
Pharmaceutical composition containing 19 types of amino acids and preparation method thereof
CN109381423A
Preparation method of compound amino acid injection
CN102302489A
Compound amino acid injection and preparation method thereof
CN102940628A
Preparation method of compound amino acid injection
CN103301120A
Compound amino acid injection and preparation method thereof
CN110507604A
Cited By
Compound amino acid injection without antioxidant and preparation method and application thereof
CN122681795A
An antioxidant-free compound amino acid injection, its preparation method and application
CN122681795B
